// App-Quantinova.ai

PB1100 : Vaccine Induced Immune Thrombocytopenia and Thrombosis (VITT) external quality assessment (EQA) scheme results and interpretations from a joint UKNEQAS BC, SSC and ECAT VITT Survey May 2021.

Researchers

Presenter

  • C. Reilly-Stitt

Principal Investigators

  • A. Lowe

  • I. Jennings

  • S. Kitchen

  • P. Meijer

  • M. de Maat

  • I. Walker

Medical Centers

  • UK NEQAS Blood Coagulation, SHEFFIELD, England, United Kingdom

  • UK NEQAS BC, Sheffield, England, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

  • ECAT Foundation (External quality Control for Assays and Tests), Voorschoten, The Netherlands, Voorschoten, Zuid-Holland, Netherlands

  • Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany, Tuebingen, Baden-Wurttemberg, Germany

Locations

  • United Kingdom

  • Netherlands

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Immune thrombocytopenia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved